Introduction
Even if metformin is unanimously considered as the first-line drug therapy in type 2 diabetes (T2DM), which treatment to be added after metformin failure remains a quite challenging issue 1, 2 . Indeed, what ever the mode of action, almost all second-drug therapies offer quite similar efficacy regarding glycated hemoglobin (HbA1c) lowering effect 1, 3 .However, T2DM is often accompanied by other conditions and risk factors, on which the various glucose-lowering agents may exert different effects that may have an impact on long-term clinical outcomes and, thereby, may influence physician's drug choice 4, 5 . Classical insulin secretagogues include sulfonylureas (still recommended because of their low cost), 2 but these glucose-lowering agents expose to a risk of potentially severe hypoglycemia, weight gain and drug-drug interactions (DDIs), which may worsen outcomes 5 . In this regard, dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the inactivation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two gastrointestinal incretin hormones, may offer new opportunities in the management of T2DM [6] [7] [8] . Indeed, GLP-1 stimulates insulin secretion and inhibits glucagon secretion in a glucose-dependent manner, which explains the minimal risk of hypoglycemia associated with such incretin-based therapies 8 .
Furthermore, GLP-1 contributes to appetite regulation and thereby may avoid or at least limit weight gain despite improvement of glucose control in T2DM patients, in contrast to what is generally observed with other glucose-lowering therapies 6, 9 . However, the positioning of DPP-4 inhibitors in the management of T2DM, especially their place compared with sulfonylureas after metformin failure [10] [11] [12] , is still a matter of debate.
Several DPP-4 inhibitors are currently available (sitagliptin, saxagliptin, vildagliptin except in United States, alogliptin only in Japan, more recently linagliptin) 7, 8, 13 . They share a similar mode of action (pharmacodynamics or PD, i.e. selective inhibition of DPP-4), but they differ by some pharmacokinetics (PK) properties 14, 15 . Because they have been mostly studied as add-on therapy to metformin 10, 16, 17 , most DPP-4 inhibitors are already available as fixed dose combination (FDC) with metformin, especially vildagliptin 18 , sitagliptin 19, 20 and saxagliptin 21 .
FDC can offer convenience, reduce the pill burden and simplify administration regimens for the patient, all conditions that may improve adherence to therapy 22, 23 .
Linagliptin is the newest DPP-4 inhibitor and is characterized by specific PK properties [24] [25] [26] [27] . The most clinically relevant specificity, relative to other already available DPP-4 inhibitors, is that linagliptin has a minimal renal excretion and a predominant biliary excretion (without previous hepatic metabolism) 14, 28 . Thus, it may be used in patients with chronic kidney disease (CKD) without dose adjustment 28 . This contrasts with other DPP-4
inhibitors, for which an appropriate dose reduction is recommended according to the decrease of the estimated glomerular filtration rate (eGFR) 29 . Therefore, linagliptin may be considered as a valuable alternative in T2DM patients with impaired renal function in whom metformin may be contraindicated 30, 31 . Furthermore, in T2DM patients who may receive metformin (because of acceptable renal function and good gastrointestinal tolerance), linagliptin may also be added to the biguanide to reach HbA1c targets in case of failure of monotherapy.
Linagliptin has also proven its efficacy and safety as a triple therapy in addition to a metformin plus sulfonylurea combination 32 . Consequently, numerous patients with T2DM are in a position to receive both metformin and linagliptin 27 . Thereby, a linagliptin plus metformin hydrochloride FDC (Jentadueto®) appears attractive for clinical use (see drug summary box).
The present paper provides a PK/PD evaluation of linagliptin plus metformin and an updated review of the randomized clinical trials and of the bioequivalence studies that have assessed both the efficacy and tolerability/safety of this linagliptin-metformin combination.
We will particularly focus our analysis on the safety profile of the combination and what might be its potential use in patients with mild to moderate CKD and in elderly subjects 
Mechanism of action of linagliptin plus metformin

Pharmacokinetic evaluation
The individual PK characteristics of metformin 35, 36 and linagliptin 24, 37 have been reviewed elsewhere. Metformin is mainly excreted by the kidneys whereas linagliptin has a negligible renal excretion. This part of the present review will focus on the PK interactions between linagliptin and metformin 38 . Only limited DDIs have been described with metformin and with linagliptin both in healthy volunteers and in T2DM patients 35, 39, 40 . (Table 2) 33 .
Food may influence the bioavailability of metformin, linagliptin or linagliptin/metformin FDC (Table 3) . Even if the bioavailability of metformin is slightly reduced by food 43, 44 , it is generally recommended to take metformin with a meal in order to improve gastrointestinal tolerance. Intake of a high-fat meal reduced the rate of linagliptin absorption (increase of T max by about 2 hours), but had no influence on the extent of absorption 45 . These findings suggest that linagliptin can be given together with metformin during a meal. The effect of food on bioavailability of linagliptin/metformin FDC was evaluated with the higher strength of metformin. Administration of linagliptin 2.5 mg/metformin hydrochloride 1000 mg FDC with a fat meal resulted in no change in overall exposure of linagliptin. There was no change in metformin AUC; however, mean peak serum concentration of metformin was decreased by 18% when administered with food, confirming previous observations when metformin was tested alone 43, 44 . Furthermore, a delayed time-topeak serum concentrations by 2 hours was observed for metformin under fed conditions.
These changes are not likely to be clinically significant 33 .
Pharmacodynamic evaluation
The two antidiabetic agents exert their glucose-lowering effects via different mechanisms, metformin essentially independently of insulin secretion whereas linagliptin primarily (although not exclusively) via its incretin action on insulin secretion 38, 46 . The antihyperglycemic effect of metformin is already marked in the fasting state, by inhibiting overnight gluconeogenesis 47 whereas the DPP-4 inhibitor generally exerts a greater glucoselowering effect in the postprandial state than after an overnight fast 48 .
The mechanism of action of metformin mainly involves suppression of hepatic glucose output and modestly reduction of insulin resistance 49, 50 . The inhibition of hepatic glucose production occurs mostly through a mild and transient inhibition of the mitochondrial respiratory chain complex I. The resulting decrease in hepatic energy status activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted mechanism for the action of metformin on hepatic gluconeogenesis 51 .
Linagliptin effectively inhibited plasma DPP-4 activity in patients with T2DM, producing immediate improvements in incretin levels (both GLP-1 and GIP), glucagon suppression, and better glycemic control 52, 53 . The improvement in glycemic control was Interestingly, almost 10 years ago already, metformin was shown to increase GLP-1 release in obese patients without or with T2DM 54, 55 . A more recent study confirmed that metformin monotherapy in obese patients with T2DM was associated with increased postprandial GLP-1 levels, including its active form, over a 6-h period following a standard mixed meal, without changes in DPP-4 activity 56 . These data confirmed that metformin-induced increase in GLP-1 levels is independent of DPP-4 inhibition after a meal 44, 57 . The mechanisms of action explaining why metformin may promote GLP-1 secretion from L cells are rather complex 58, 59 . Recent experimental studies in rats suggested that metformin enhances circulating levels of GLP-1 through a peripheral muscarinic (M3) and gastrin-releasing peptide (GRP) receptor-dependent mechanism 58 . It has also been shown that metformin protects against lipoapoptosis (possibly by blocking JNK2 activation), and enhances GLP-1 secretion from GLP-1-producing cells in vitro 59 . Finally, in a recent study in T2DM patients, whose results contrast with some previous observations 42, 56 , the use of metformin was associated with a significantly lower DPP-4 activity, independently of age, sex, body mass index and HbA1c
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. All together, the combination of a DPP-4 inhibitor and metformin led to greater increases in active GLP-1 than either treatment alone 57 , which may represent a further argument in favor of this combination and the commercialization of a gliptin-metformin FDC 61 .
Clinical applications
Addition of linagliptin to metformin monotherapy (Table 4)
All clinical trials having tested the addition of linagliptin to metformin were performed in T2DM patients not well controlled (HbA1c 6.5-7% to 10-11%) with a dose of metformin ≥1500 mg/day or maximally tolerated dose. The follow up was rather short (12-24 weeks in placebo-controlled studies), except in one trial comparing linagliptin with glimepiride (104 weeks).
Comparison versus placebo
The efficacy and safety of linagliptin, added to ongoing metformin therapy, were assessed in 333 patients with T2DM who had inadequate glycemic control with metformin vs.18.9%) and no increased risk of hypoglycemia was observed.
As metformin is administered twice daily, a FDC of these compounds would require twice-daily administration of linagliptin. Therefore, a study evaluated whether 2.5 mg twicedaily dosing of linagliptin has comparable efficacy and safety to 5 mg once-daily dosing when given in addition to metformin twice daily in patients with inadequate glycemic control 64 . A total of 491 T2DM patients were randomized to double-blind treatment with linagliptin 2.5 mg twice daily, 5 mg once daily or placebo, respectively, in addition to continuing metformin twice daily. After 12 weeks, linagliptin 2.5 mg twice daily and 5 mg once daily both significantly reduced HbA1c [placebo-adjusted changes from baseline (mean level :
7.97%) -0.74% (95% CI -0.97, -0.52) and -0.80% (95% CI -1.02, -0.58), respectively, both
The treatment difference (twice daily -once daily) between the linagliptin regimens was 0.06 (95% CI -0.07, 0.19), the upper bound of which was less than the predefined noninferiority margin (0.35%). Hypoglycemia was rare and similar to placebo, with no severe episodes.
Comparison versus a sulfonylurea
In a 2-year double-blind trial, T2DM patients on stable metformin alone or with one additional oral antidiabetic drug (washed out during screening) were randomly assigned to linagliptin (5 mg; n=777) or glimepiride (1-4 mg; n=775) orally once daily in addition to metformin (daily dose ≥ 1500 mg in 93% of patients) 65 . Reductions in adjusted mean HbA1c from baseline (7.69% in both groups) to week 104 were similar in the linagliptin (-0.16%) and glimepiride groups (-0.36%; difference 0.20%, 97.5% CI 0.09-0.30), meeting the predefined non-inferiority criterion of 0.35%. Fewer participants had hypoglycemia or severe hypoglycemia with linagliptin compared with glimepiride (see below : 4.3).
Initial linagliptin-metformin combined therapy
A potential benefit of early combined therapy in the management of T2DM may be explained by the complex pathophysiology of the disease and the numerous organ defects that may be targeted by various pharmacological interventions 66 . Because of the complementary mode of action between metformin and a DPP-4 inhibitor, it may sound clinically appealing to initiate a gliptin-metformin combination 38, 61 .
The efficacy and safety of initial combination therapy with linagliptin plus metformin versus linagliptin or metformin monotherapy in patients with T2DM were evaluated in a large (n=791) 24-week, double-blind, placebo-controlled, Phase III trial 67 . Two free combination therapy arms received linagliptin 2.5 mg twice daily + either low (500 mg) or high (1000 mg) dose metformin twice daily. Four monotherapy arms received linagliptin 5 mg once daily, metformin 500 mg or 1000 mg twice daily or placebo. Patients with HbA1c ≥11.0% were not eligible for randomization and received open-label linagliptin + high-dose metformin. The placebo-corrected mean change in HbA1c was superior with the two initial combined therapies compared to either monotherapy or placebo (Table 5) . In the open-label arm, the mean change in HbA1c from baseline (11.8%) was -3.7% 68 . Hypoglycemia occurred at a similar low rate with linagliptin+metformin as with metformin alone.
Safety evaluation
The safety profiles of each separate glucose-lowering agent, the biguanide compound metformin 4, 49, 50 or the DPP-4 inhibitor linagliptin 24, 69, 70 , are well documented. The most commonly reported adverse effects associated with metformin therapy are gastrointestinal, and include abdominal pain, diarrhea, nausea, and anorexia. Generally these digestive adverse events may be minimized by initiating a low dose of metformin, gradually uptitrating the metformin dose, and administering the medication with meals. Using this approach, digestive symptoms occurred in around 10 % of the patients receiving metformin as monotherapy in the US multicenter metformin study, and diarrhea and nausea were characterized as severe in only 8% and 4% of patients, respectively 71 . The most critical adverse event related to metformin therapy is lactic acidosis, but it is a rare complication provided that contraindications of metformin use are respected, including CKD (see below) 72 .
The safety profile of linagliptin has been analyzed in detail in previous dedicated reviews 24, 69, 70 and is generally good and quite similar to that previously reported with other DPP-4 inhibitors (i.e. almost comparable to that of placebo) 8, 73, 74 . The long-term (52 weeks) safety and tolerability of oral linagliptin at either 5 or 10 mg were recently confirmed in an extension study of a phase III trial with T2DM Japanese patients with T2DM 75 . Overall the safety/tolerance profile of linagliptin-metformin coadministration is similar to that of metformin alone (Table 5 ).
General tolerance profile
The safety of concomitantly administered linagliptin (daily dose 5 mg) and metformin (mean daily dose of approximately 1800 mg) has been evaluated in 2816 patients with T2DM treated for ≥12 weeks in clinical trials. Three placebo-controlled studies with linagliptin + metformin were conducted : 2 studies were 24 weeks in duration, 1 study was 12 weeks in duration. In the 3 placebo-controlled clinical studies, adverse events which occurred in ≥5% of patients receiving linagliptin + metformin (n=875) and were more common than in patients given placebo + metformin (n=539) included nasopharyngitis (5.7% vs 4.3%) 33 . In a 24-week factorial design study, adverse events reported in ≥5% of patients receiving linagliptin + metformin were more common than in patients given placebo (nasopharyngitis : 6.3 vs. 1.4%; diarrhea : 6.3 vs. 2.8%) and only slightly higher than with either monotherapy 67 . Of note, because of the physiological (instead of supraphysiological or pharmacological) levels of GLP-1 reached with the DPP-4 inhibitor, the addition of linagliptin to metformin therapy does not appear to cause a greater incidence of gastrointestinal side effects than does metformin alone.
Effects on body weight
Overall, no clinically relevant changes in body weight were observed with linagliptin added to metformin, contrasting with the weight gain commonly observed with other glucoselowering agents 6 . In a pooled analysis of 24-week phase III trials followed by a 
Effects on hypoglycemia
As already mentioned, the likelihood of treatment-related hypoglycemia is very low with the dual metformin plus linagliptin comnibation. This is explained by the absence of insulin-secreting effect of metformin (in contrast metformin is commonly associated with an insulin-sparing effect) 49, 50 and by the glucose-dependent potentiation of insulin secretion of linagliptin (a property shared by all DPP-4 inhibitors leading to increased GLP-1 levels) 77 . 
Effects on pancreatitis and pancreatic cancer
Because patients with T2DM exhibit significantly increased rates of acute pancreatitis, large case control studies are required to ascertain whether a specific antidiabetic therapy independently modifies the risk of developing pancreatitis 79 . DPP-4 inhibitors, by increasing GLP-1 levels, were suspected to be associated with an increased risk of pancreatitis and even pancreatic cancer 80 . In a controversial paper that examined the US FDA database of reported adverse events, the use of sitagliptin was shown to increase the odds ratio for reported pancreatitis 6-fold (an increase almost similar to that noticed for the GLP-1 receptor agonist exenatide) as compared with other glucose-lowering therapies 81 . However, reporting bias may be suspected to explain these observations. In a general review on the tolerability of DPP-4 inhibitors, pancreatitis was reported at lower rates with gliptins compared with other oral antihyperglycemic agents 73 .
In the large database on linagliptin, no case of acute pancreatitis (1 chronic pancreatitis among 2523 patients) and no case of pancreatic cancer have been described 69 . The conclusion of a recent review was that the available data set from multiple independent sources does not currently support a mechanistic or epidemiological link between incretin therapies and the development of acute pancreatitis; however, longer studies with greater numbers of patients are needed for more robust conclusions to be drawn 
Effects on cardiovascular events
T2DM is associated with a higher risk of CV events and some glucose-lowering agents may be associated with an increased rather a decreased risk of CV events. Therefore, especially since the rosiglitazone story, the FDA now requests that new glucose-lowering agents demonstrate CV safety 84 . Metformin may be associated with a lower incidence of CV events when the drug is used as monotherapy 
Safety concern in patients with CKD
Because patients with T2DM are better protected against CV disease and thereby live longer, more and more patients are exposed to the development of CKD 90 . Thus, the efficacy and more especially the safety of a gliptin plus metformin combination in patients with CKD deserve much attention 91 .
Linagliptin in patients with CKD
The influence of various degrees of renal impairment on the exposure of linagliptin was assessed in subjects with and without T2DM Because metformin is classically contraindicated in patients with renal impairment, GFR < 60/min was considered an exclusion criterion in all these trials and thereby the linagliptin plus metformin combination has not been evaluated in patients with moderate to severe CKD.
Metformin in patients with CKD
The use of metformin is classically contraindicated in patients with CKD, as stated in the labeling of the drug. However, the biological criteria used to define CKD may vary between countries. Today's U.S. Food and Drug Administration prescribing guidelines for metformin contraindicate its use in men and women with serum creatinine concentrations ≥ 1.5 and ≥ 1.4 mg/dL (≥ 132 and ≥ 123 mmol/L), respectively. According to the EU label, metformin is contraindicated in patients with a creatinine clearance < 60 ml/min and this parameter should be determined before initiating treatment and regularly thereafter. There is an ongoing debate, however, as to whether these thresholds are too restrictive and that those T2DM patients with mild-moderate renal impairment would gain more benefit than harm from using metformin. 
Safety concern in the elderly T2DM patients
Because of their overall safety profile, especially the negligible risk of hypoglycemia, DDP-4 inhibitors are attractive for the management of elderly patients with T2DM 96, 97 . A large cohort study of elderly (> 65 years) patients with T2DM uncontrolled on metformin alone showed that the incidence of hypoglycemia was three times higher in patients prescribed a conventional oral antidiabetic drug (a sulfonylurea in most instances) versus a DPP4 inhibitor after 6 months (incidence of hypoglycemia/severe hypoglycemia : 
Linagliptin plus metformin FDC
The linagliptin plus metformin FDC has been developed as tablets with three different dosage forms and strengths to be administered twice daily : linagliptin 2. Linagliptin plus metformin combination, given separately, has proven its superiority as compared to either monotherapy, with a good safety profile 67 . However, there is no study having evaluated the long-term effect of the FDC linagliptin plus metformin so far.
Conclusion
The combination of metformin, the first choice glucose-lowering drug, and a DPP-4 inhibitor such as linagliptin sounds as a valuable option in the management of patients with T2DM. Indeed, the two compounds act via different, albeit complementary, mechanisms leading to an additive glucose-lowering activity. Together, the two compounds tackle various main defects in the pathophysiology of T2DM, i.e. impaired insulin secretion, increased glucagon levels, increased hepatic glucose production and decreased insulin sensitivity, resulting in significant reductions in both fasting and posprandial glucose plasma concentrations. Statistically significant and clinically relevant reductions in HbA1c levels have been described when linagliptin 5 mg was added in patients not reaching individually selected HbA1c targets with metformin alone or even with metformin plus sulfonylurea therapy. There are no clinically relevant PK DDIs between linagliptin and metformin reported so far and no major influence of food on PK of either compound has been described.
Linagliptin 2.5 mg twice daily had non-inferior HbA1c-lowering effects compared to 5 mg once daily, with comparable safety and tolerability, in T2DM patients inadequately controlled with metformin. These observations open the door to the launch of a linagliptin plus metformin FDC to be given twice daily with a meal.
Overall, the safety profile of linagliptin is comparable to that of placebo, even when the DPP-4 inhibitor is combined with metformin; in particular, there is no worsening of the well known gastrointestinal side effects of the biguanide present in some patients. No special adverse effects have been reported, especially no weight gain and no severe hypoglycemia, so that this combination may be used safely in a large proportion of patients with T2DM, including elderly people, even if some concern remains in presence of CKD.
Linagliptin may be used in T2DM patients with any degree of renal impairment, 
Drug summary box
Drug name (generic) Linagliptin plus metformin (Jentadueto®) Phase
Approval by FDA and EMA Indication 1) as an adjunct to diet and exercise to improve glycemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone; 2) in those already being treated with the combination of linagliptin and metformin; and 3) in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. Pharmacology Linagliptin = Inhibitor of dipeptidyl peptidase-4 (DPP-4) = incretin-based therapy description/mechanism of action Metformin = AMPK activator = inhibition of hepatic glucose output 
EXPERT OPINION
All diabetes guidelines recommend metformin, if not contraindicated and if well tolerated, as the preferred and most cost-effective first pharmacological agent for the management of type 2 diabetes (T2DM). If monotherapy does not achieve/maintain glycated hemoglobin (HbA1c) target, adjusted to patient's individual pattern, the next step would be to add a second glucose-lowering agent. Choice is based on patient characteristics and drug properties, with the overriding goal of improving glycemic control while minimising side effects. In this regard, the addition of a dipeptidyl peptidase-4 (DPP-4) inhibitor may offer potential benefits over classical sulfonylureas in T2DM patients, despite a higher cost. A lower risk of hypoglycemia and weight gain is already well demonstrated with a gliptin as compared to a sulfonylurea, despite an almost comparable reduction in HbA1c level. This advantage was confirmed with linagliptin compared to glimepiride. The negligible risk of hypoglycemia associated with DPP-4 inhibition is of major interest, especially in subjects at higher risk such as elderly people and patients with renal insufficiency.
Another potential advantage of DPP-4 inhibitors may consist in a better B-cell protection, which should result in a longer durability of the glucose-lowering activity. Indeed, sulfonylureas are generally associated with a progressive, and sometimes quite rapid, deterioration of glucose control, even when added to metformin. This failure requires increased complexity of the glucose-lowering therapy with the progression to a strategy including a triple oral treatment or the use of injections (GLP-1 receptor agonists or insulin). However, clinical evidence remains scarce in humans and further studies should demonstrate whether gliptins really offer a better durability of glucose control compared to sulfonylureas. The recent 2-year data of a controlled trial comparing linagliptin with glimepiride in patients with T2DM not well controlled with metformin monotherapy are insufficient to draw any firm conclusion in this regard.
A further potential benefit of a DPP-4 inhibitor compared to a sulfonylurea might be a better cardiovascular (CV) protection. Indeed, since the University Group Diabetes Program (UGDP) in the seventies, the CV safety of sulfonylureas remains questionable. The results of the United Kingdom Prospective Diabetes Study (UKPDS) in the late nineties were not completely reassuring with the demonstration of an unexplained higher risk in T2DM patients receiving a metformin-sulfonylurea combination. In contrast, all available data with DPP-4 inhibitors support the CV safety of this incretinbased therapy and suggest a CV protection versus placebo or an active comparator. Considering the high CV risk commonly associated with T2DM, the fact that gliptins could offer a better CV protection than sulfonylureas in patients not well controlled with metformin would be of major interest in clinical practice. This hypothesis is currently evaluated in the CAROLINA ("CARdiovascular Outcome study of LINAagliptin versus glimepiride in patients with T2DM") prospective trial comparing linagliptin with glimepiride. This is the only prospective trial comparing a DPP-4 inhibitor with an active compound as all other ongoing trials are comparing alogliptin, saxagliptin or sitagliptin versus a placebo.
In the recent ADA-EASD position statement, initial combination drug therapy is limited to patients with a high baseline HbA1c (e.g. ≥9.0% [≥75 mmol/mol]) who have a low probability of achieving a nearnormal target with monotherapy. Introducing initial combination therapy (instead of metformin alone) when pharmacological treatment is required makes sense considering the complexity of the pathophysiology of T2DM, in order to reach therapeutic goal at an earlier stage, have a better stabilisation of this evolving disease and avoid or delay subsequent more complex therapies. Because the complementary effects of linagliptin and metformin lead to robust and sustained improvements in glycemic control, initial combination of the two agents may be considered as a useful treatment option for patients with T2DM as it reulst in better glucose control than either monotherapy, with a similar good tolerance profile.
By increasing convenience and thereby patient's adherence, a fixed-dose combination (FDC) may offer some advantages in clinical practice. That is the reason why several gliptin plus metformin FDCs are now available, the most recently proposed one being Jentadueto® (linagliptin plus metformin). Adherence to therapy is, indeed, a major concern in patients with T2DM who generally share several chronic comorbidities and thus should receive multiple medications. However, as the classical formulation of metformin hydrochloride should be given twice daily, the linagliptin plus metformin FDC has also to be given twice daily while once daily administration of linagliptin is enough to maintain sustained DPP-4 inhibition over 24 hours. Because metformin should be titrated to improve gastrointestinal tolerance, various FDC forms with different strengths of metformin have been developed. If the use of metformin would be extended to patients with mild to moderate renal impairment in the future, this may also allow the prudent use of such combination, with a reduced metformin dosage, in these circumstances.
Linagliptin has a unique pharmacokinetic profile compared to other DPP-4 inhibitors, with a very low renal excretion. This characteristic allows use linagliptin in T2DM patients with chronic kidney disease (from mild to severe) without contra-indication and any dose adjustment. Considering the large number of patients with some degree of renal impairment (especially in the elderly population), this may represent an advantage over other DPP-4 inhibitors whose daily dose should be adjusted according to the reduction of estimated glomerular filtration rate (eGFR). However, the situation of Juntadueto®) is less clear because of the presence of metformin. Indeed, renal impairment (eGFR < 60 ml/min) is considered as an official contraindication of metformin because of the potential risk of lactic acidosis in case of biguanide accumulation. Nevertheless, there is an ongoing debate as to whether these thresholds are too restrictive and thereby not allow patients with mild-moderate renal impairment gain more benefit than harm from using metformin. In the recent ADA-EASD position statement, it is considered that metformin may be used down to a GFR of 30 ml/min, with dose reduction advised below 45 ml/min. If so, the use of linagliptin plus metformin, either separately or as FDC, would be extended to a larger population of patients with T2DM and the specific advantage of linagliptin regarding its use independent of renal function would even be better appreciated in clinical practice.
